9折“卖子”，金种子酒“弃药从酒”落地，主业突围仍艰难

Core Viewpoint - The divestiture of Anhui Jintai Pharmaceutical Co., Ltd. by Jinzhongzi Liquor marks a strategic shift to focus on its core liquor business and alleviate financial pressure, although the effectiveness of this move in reversing the company's ongoing losses remains uncertain [2][4]. Summary by Sections Asset Divestiture - Jinzhongzi Liquor has completed the divestiture of its pharmaceutical business, which has been in progress since April 2024, when it announced the intention to publicly transfer 92% of its stake in Jintai Pharmaceutical [2][3]. - The stake was initially listed at an assessed value of 140 million yuan but was sold for 126 million yuan after a 10% price reduction due to a lack of qualified buyers, indicating a "fire sale" approach [2][3]. - Jintai Pharmaceutical, established in 2000, reported revenues of 161 million yuan and a net profit of 6.19 million yuan in 2024, with a net asset value of 130 million yuan as of September 2025, making the sale price close to its book value [3]. Financial Performance and Challenges - Jinzhongzi Liquor has faced significant financial difficulties, being the only loss-making company among four listed liquor firms in Anhui, with cumulative losses exceeding 600 million yuan from 2021 to 2024 [4]. - In Q3 2025, the company reported a revenue of 144 million yuan, a year-on-year increase of 3.73%, but still incurred a net loss of 28.3 million yuan, indicating that cost-cutting rather than revenue growth was the primary driver of this improvement [4]. - The company has a total interest-bearing debt of 375 million yuan, surpassing its cash reserves, and has experienced negative operating cash flow, with cumulative outflows exceeding 1.2 billion yuan [4]. Strategic Focus and Management Issues - Despite efforts to streamline its product line and focus on high-end liquor, the company has struggled, with high-end liquor sales only increasing by 7.33%, while mid-range and low-end liquor revenues declined by 24% and 23.83%, respectively [4][5]. - Frequent changes in the management team, including the resignation of key executives, have raised concerns about strategic continuity and the integration of new management from shareholder China Resources Group [5].